Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05492500 · ClinicalTrials.gov registry record · Phase 2
A Study of Ponsegromab in People With Heart Failure
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 455
- Enrollment target
NCT05492500 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 455 participants.
The verdict
NCT05492500, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 455 participants
- Enrollment target
Study Summary
The primary purpose of this clinical trial is to compare the effects of study medicine (Ponsegromab/PF-06946860) with a placebo (an injection that looks like the study medicine but does not contain the active medicine) to find out if the study medicine is better than the placebo (an injection that looks like the study medicine but does not contain the active medicine) for treatment of symptoms related to heart failure. Participants will not know which treatment group they are assigned to. Most participants in this study will receive the study medicine or placebo by shots under the skin every four weeks. People may be able to participate in this study if they have heart failure. Participants will take part in this study for about 9 months. During this time participants will visit the study clinic once a month. A separate PK cohort within this clinical trial will receive open-label study medicine (Ponsegromab/PF-06946860) only. Participants in this open-label, PK cohort will not receive placebo. These participants will receive the study medicine by shots under the skin every four weeks. People may be able to participate in this study cohort if they also have heart failure. Participants will take part in the open-label, PK cohort for about 7 months.
Interventions
- DRUG Main cohort (Cohort A): Ponsegromab low dose
- DRUG Main cohort (Cohort A): Ponsegromab medium dose
- DRUG Main cohort (Cohort A): ponsegromab high dose
- OTHER Main cohort (Cohort A): Matched placebo
- DRUG Open-label, PK Cohort (Cohort B): ponsegromab low dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2022-09-26 |
| Est. Completion | 2025-03-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05492500
The ClinicalTrials.gov registry entry for NCT05492500 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 455 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Main cohort (Cohort A): Ponsegromab low dose is the first listed.
NCT05492500 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05492500 about?
NCT05492500 is a clinical study titled "A Study of Ponsegromab in People With Heart Failure". The primary purpose of this clinical trial is to compare the effects of study medicine (Ponsegromab/PF-06946860) with a placebo (an injection that looks like the study medicine but does not contain the active medicine) to find out if the study medicine is better than the placebo (an injection that l...
What is the current status of trial NCT05492500?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 455 participants. The study started on 2022-09-26. Estimated completion is 2025-03-05.
What interventions are being tested in trial NCT05492500?
The interventions under investigation include: Main cohort (Cohort A): Ponsegromab low dose (DRUG), Main cohort (Cohort A): Ponsegromab medium dose (DRUG), Main cohort (Cohort A): ponsegromab high dose (DRUG), Main cohort (Cohort A): Matched placebo (OTHER), Open-label, PK Cohort (Cohort B): ponsegromab low dose (DRUG).
Who is sponsoring clinical trial NCT05492500?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.